雑誌文献を検索します。書籍を検索する際には「書籍検索」を選択してください。

検索

書誌情報 詳細検索 by 医中誌

Japanese

Postmarketing phase vigilance for garenoxacin in the patients with pneumonia with respiratory disease Izumikawa Koichi 1 , Watanabe Akira 2 , Miyashita Naoyuki 3 , Ishida Tadashi 4 , Kushimoto Satoru 5 , Takagi Hiroyasu 6 , Kohno Shigeru 7 Keyword: ガレノキサシン , レスピラトリーキノロン系抗菌薬 , 肺炎 , 呼吸器疾患 pp.131-146
Published Date 2017/4/25
DOI https://doi.org/10.20837/2201705131
  • Abstract
  • Look Inside
  • Reference

 The clinical efficacy of garenoxacin, administered at a dose of 400 mg once daily, was re-analyzed for bacterial or atypical pneumonia in patients with disease related to lung or chronic respiratory disease in postmarketing phase vigilance. The clinical efficacy rate at the end of treatment was about 90%with pneumonia in patients with disease related to lung or chronic respiratory disease, and was decreased 80 to 83% in patients of male with more than 65 years old, in patients whose spread of chest X-ray shadow was more than one-third to less than two-thirds of one side lung. From above findings, garenoxacin can be useful in clinical practice for the treatment with pneumonia in patients with disease related to lung or chronic respiratory disease. And in treatment of those patients, it is important to treat in consideration of patient backgrounds, such as gender, age, and spread of chest X-ray shadow.



基本情報

電子版ISSN 印刷版ISSN 0913-2384 医薬ジャーナル社

関連文献

もっと見る

文献を共有